U.S. Markets close in 4 hrs 34 mins

AmerisourceBergen Corporation (ABC)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
103.26+0.95 (+0.93%)
As of 11:23AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close102.31
Bid103.28 x 800
Ask103.29 x 800
Day's Range101.60 - 103.44
52 Week Range72.06 - 106.45
Avg. Volume1,142,818
Market Cap21.08B
Beta (5Y Monthly)0.60
PE Ratio (TTM)13.71
Earnings DateN/A
Forward Dividend & Yield1.68 (1.64%)
Ex-Dividend DateAug 14, 2020
1y Target EstN/A
  • Business Wire

    AmerisourceBergen Reports Fiscal 2020 Third Quarter Results

    AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third quarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1 percent to $1.85 in the fiscal third quarter.

  • Business Wire

    AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2020 Earnings Release

    AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter Fiscal 2020 on Wednesday, August 5, 2020, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2020.

  • AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
    Business Wire

    AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™

    AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.